Dry Eye Syndrome Market Research Report, By Type (Evaporative, Aqueous), By Diagnosis (Schirmer Test, Eye Exam), Treatment (Nutritional Supplements, Surgery), Distribution Channel (Hospital Pharmacies) End User (Hospitals) -Forecast Till 2030

Dry Eye Syndrome Market Overview:

Dry Eye Syndrome Market is expected to reach USD 5,080.0 Million by 2030 at 5.31% CAGR during the forecast period 2022-2030

The symptoms of dry eye syndrome are redness, irritation, discharge and may even lead to blurred vision in severe cases.

Dry eye syndrome is a condition where there is less lubrication in the eyes due to less tear production or due to quick evaporation of tears. This condition may arise due to internal problems such as meibomian gland dysfunction, vitamin deficiency, surgery, use of contact lens, or due to external agents like medications and exposure to dust and smoke. The dry eye syndrome market size is expected to grow at a Compound Annual Growth Rate CAGR of 6.6 % over the forecast period.

Rapid advancements in ophthalmology and the development of affordable drugs are bringing positive impacts on the market. Moreover, increasing awareness among commoners regarding the treatment of minor eye problems will further increase the market value. The dry eye syndrome market value is estimated to be worth USD 8.1 billion by the end of the current forecast period in 2028. 

Covid 19 Analysis

Covid-19 had a negative impact on the dry eye syndrome market. The rapid surge in coronavirus cases made healthcare workers shift attention to covid management thereby putting other cases in shadow. The restrictions in the movement of goods and people caused a shortage of eye care medicines in the market. Moreover, it also led to a downfall in the number of patients visiting hospitals and clinics for treatment. However, there was a boom in the growth of online medical counseling and online pharmaceutical sales. The market is showing rapid recovery post covid relaxations.

Market Dynamics

Drivers

The increasing prevalence of eye disorders owing to a lifestyle change is the major factor driving the growth of the global dry eye syndrome market. Moreover, the rise in the geriatric population and increasing incidence of lifestyle diseases like diabetes, obesity, hypertension, etc. is also fueling the market growth.

There has been a considerable rise in awareness about the dry eye problem and the need for its treatment. This along with advancements in treatment procedures is likely to boost the market growth. Moreover, increasing government spending and private investments in the development of the healthcare sector are bringing better prospects for the global dry eye syndrome market.

Restraints

The delay in the drug approval process and lack of skilled ophthalmologists are the major factors restraining the growth of the global dry eye syndrome market. Stringent drug approval mechanisms of testing bodies lead to delay in the launch of new drugs in the market. The lack of skilled medical personnel in primary healthcare centers in underdeveloped nations leads to ignorance of symptoms of dry eye problems by patients thereby hampering the growth of the dry eye syndrome market. 

Technology Analysis

Dry eye syndrome is a condition where there is a lack of tears or lubrication in the eyes. It occurs mainly when the eye does not produce sufficient tears or when the tears evaporate too quickly from the eyes. It is also known as keratoconjunctivitis sicca (KCS) and is prevalent among 5-30 % of the global population to some degree.

There may be various underlying causes for this problem. Some of the major causes are due to use of contact lenses, meibomian gland dysfunction, pregnancy, Sjögren syndrome, vitamin A deficiency, omega-3 fatty acid deficiency, LASIK eye surgery. Moreover, the use of medications such as antihistamines, some blood pressure medication, hormone replacement therapy, and antidepressants may also lead to the problem.

Treatment of this problem depends upon the underlying cause. The major treatment categories are avoidance of exacerbating factors, tear stimulation and supplementation, increasing tear retention, and eyelid cleansing and treatment of eye inflammation.

Study Objectives

The specific objectives of this market report on the global dry eye syndrome market are given below:

• To provide a complete overview of the dry eye syndrome market.


• To analyze and forecast the dry eye syndrome market in terms of value and volume.


• To provide information about the impact of covid 19 on the dry eye syndrome market


• To identify the problems and prospects of the dry eye syndrome market


• To give details about the technological know-how of the product.


• To provide a comprehensive analysis of the regional market and the potentially growing segments.


• To identify the key players of the dry eye syndrome industry.

Segment Analysis

By Type

• Evaporative dry eye syndrome


• Aqueous dry eye syndrome


• others

The evaporative dry eye syndrome segment holds the largest Market share by disease type. It accounts for about 80 % of the dry eye syndrome problem. It occurs due to malfunction of the meibomian gland in eyelids. It is unable to form a thin lipid layer to prevent the tears from evaporating.

By Treatment

• Nutritional supplements


• Serum eye drops

Lubricant Eye Drops

• Oily tear eye drops ointments


• Preservative-free drops


• Others

Anti-inflammatory Drugs

• Tetracyclines


• Corticosteroids


• Others

Surgery

• Punctal occlusion


• Intense pulsed light therapy


• Others

Anti-inflammatory drugs account for the largest market share. These drugs are potent in treating dry eyes and reduce inflammation due to rubbing or allergens.

By Delivery System

• Liquid


• Gel


• Ointment


• Others

The liquid segment accounted for the largest dry eye syndrome market share. Liquid drops are easy to apply and thereby are in high demand. They help to keep the eye moist and in the quick remedy of dry eye symptoms such as burning, itching, etc.

By Distribution Channel

• Hospital pharmacies


• Retail pharmacies


• Online pharmacies


• Others

Retail pharmacies are the largest segment by distribution channel of the Global dry eye syndrome market. The vast network of retail pharmacies makes them close to patient customers. Moreover, easy access and buying procedures are growth-promoting factors. However, the online pharmacies segment is witnessing a higher growth rate owing to the increasing penetration of the internet. 

By End-users

• Hospitals


• Clinics


• Home care


• Others

Hospitals are the dominating end-user segment of the global dry eye syndrome market. It is a primary place of treatment for most of the global population. Therefore, it accounts for the huge demand for eyecare medicines and devices.

Regional Analysis

The different regional markets for the global dry eye syndrome market are:

• Americas

• US


• Canada


• Mexico


• South America

• UK


• Germany


• France


• Italy


• Spain


• Rest of Europe

• China


• India


• Japan


• Australia & New Zealand


• Rest of Asia-Pacific

• The Middle East


• Africa.

The American region holds the largest market share of the global dry eye syndrome market. The rising prevalence of eye diseases and the growing geriatric population are the major growth-boosting factors in this region. Moreover, huge government funding towards the development of medical specialty centers like eye centers is driving the market growth in this region.

Asia-Pacific is the fastest-growing regional segment. The rapid development of healthcare infrastructure and rising awareness about the treatment of eye problems are key growth drivers in this region.

Competitive Landscape

The major global companies playing a key role in the dry eye syndrome market are:

• Allergan (Republic of Ireland)


• Novartis AG (Switzerland),


• Otsuka Pharmaceutical Co. Ltd. (Japan)


• Valent Pharmaceuticals (Canada)


• Johnson & Johnson Vision (U.S.)


• Acadia Pharmaceutical (U.S.)


• Allostera Pharma (Canada)


• I-Med Pharma Inc. (Canada)


• Santen Pharmaceuticals Co. Ltd., (Japan)


• AFT Pharmaceuticals (New Zealand)


• Novaliq GmBh (Germany)


• Auven therapeutics (U.S.)

Recent Developments

• In October 2020, Kala Pharmaceuticals, a leading biopharmaceutical company, received FDA Approval of Dry Eye Disease Treatment Vesuvius (loteprednol etabonate ophthalmic suspension 0.25%). It is the first ocular corticosteroid for the treatment of dry eye disease and the first drug approved specifically for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease.


• In July 2019, Novartis announced the acquisition of ‘Xiidra’. Xiidra is the first and only prescription treatment approved by the U.S. FDA for both signs and symptoms of dry eye disease, with a mechanism of action that targets inflammation.

Intended Audience

This report will be beneficial for every stakeholder of the dry eye syndrome market such as:

• Pharmaceutical companies


• Medical Research and Development Institutes


• Ophthalmologists


• Dry eye syndrome patients


• Potential Investors

Report Overview

This report provides an in-depth analysis of the dry eye syndrome market in terms of current value and future forecast. We have also identified the problems and prospects of the given market.

Moreover, technological analysis of the product will greatly help to make decisions about investment in the product. Furthermore, this report contains a detailed analysis of every segment of the given market for the current forecast period. This report has also highlighted the key players and the current developments in the dry eye syndrome market.